Myriad Investor Day 2023 replay is now available. Watch now
Let’s talk about your next project
Empowering patients, researchers, and physicians to select the best therapies for precision disease treatment
Pharmaceutical and biotech partners can leverage our CDx development capabilities for custom end-to-end projects.
Our dedicated team has supported hundreds of clinical trials and can lend our expertise in genetics and CDx to your patient samples.
For more than 30 years, we’ve driven industry-leading advances in genetics. Myriad completed the initial cloning of BRCA1 and BRCA2 in the 1990s, and today we’re advancing our understanding of homologous recombination deficiency and the genetics of cancer risk — but we’re just getting started.
Our extensive regulatory work throughout the United States, Europe and Japan uniquely positions Myriad as a valuable, experienced partner in navigating regulatory agencies worldwide.
With labs in the U.S. and a partnership in China, Myriad can receive and test samples from all over the world, benefitting patients, researchers, physicians, and pharmaceutical companies around the globe.